A photo of melanoma on a patient's skin. (Wikimedia/NCI/PD)
Oct. 10, Dr. Georgina Long announced an experimental melanoma drug that helps control brain metastases and reduce the size of brain tumors. She gladly pronounced the success of the phase two trial of the oral drug to the congress of European Society for Medical Oncology (ESMO). Dr. Long also facilitated the first clinical trial of the melanoma medicine. The third stage of the experiment will be held in July next year.
What is Melanoma?
Melanoma is a skin cancer. It is an abnormal production of melanin-producing cells. Melanin gives the skin its color, and the onset of the disease is excess discoloration in the skin. Sometimes, it could be mistaken as a mole. It may also start in the eyes or intestines. The mole-like appearance is easily distinguished by its irregular shape, uneven border, rapid growth and painful sensation. It has the highest number of death cases among skin cancers, though it is curable.
Genetics and tanning beds, which emit ultraviolet rays, are some of the causes of this condition. Excessive sun exposure, especially during the hottest part of the day, can be the causative factor. The prognosis of the disease is good if detected and diagnosed early. The treatment focuses on the prevention of aggravating complications such as brain metastasis or growth of tumors. The new experimental drug is a good innovation from the company because this disorder is resistant to therapy, especially in the latent stage.
Experimental Drug
GSK2118436 is the tentative research name provided by GlaxoSmithKline. Dr. Long used 10 subjects with brain metastasis melanoma. Based on the outcome of the experiment, all the sample representatives had control of the spread of the cancerous cells in the brain. Fortunately, nine of them revealed a significant decrease of the tumor, and the success of the drug became widely accepted.
The pharmaceutical company approved the third phase of the trial and re-tested its quality. There were also corporations that had the same results, like Roche Pharmaceuticals and Bristol-Myers Squibb. In its final screening, PLX4032 and Ipilimumab were the treatments that showed qualified effect. The new experimental drug is expected to show the same relevant upshot with its late-stage development.
Hope For Melanoma Patients
Based on the American Cancer Society, this year about 68,130 new melanoma cases will be diagnosed in the United States. There will be an estimated 38,870 men and 29,260 women affected. It is common to young women and older white men. The statistics showed a bigger possibility on the increasing incidence of melanoma. If you see any signs on your skin but are unable to seek medical help because of the lack of funds, you may want to consider taking out a payday loan or for a cash advance to help with the fees. It could provide the help you need, physically and financially.
The wide researche conducted by several scientists and physicians can alleviate the consequences of melanoma. The newest experimental drug is another hope for the reduction of the severity of the disease. The simplest strategy to detect or prevent such an illness is health awareness. Medical consultation is also advised by the U.S. Food and Drug Administration (FDA).
